Good news comes in twos for Topcon

Article

Topcon Medical Systems has received FDA approval for its 3D OCT-1000. Meanwhile, the firm has also announced that it is to become the sole European distributor of OptiMedica's Pascal Photocoagulator.

Topcon Medical Systems has received FDA approval for its 3D OCT-1000. Meanwhile, the firm has also announced that it is to become the sole European distributor of OptiMedica's Pascal Photocoagulator.

The 3D OCT-1000 is the first Fourier-domain optical coherence tomography (OCT) with a colour, non-mydriatic retinal camera. It is designed to provide high-resolution cross sectional imaging of the retina to aid in the diagnosis and monitoring of various pathologies, including retinal detachments, macula holes, age-related macular degeneration and glaucoma.

Topcon has also entered into an agreement with OptiMedica whereby Topcon Europe Medical B.V., the European subsidiary of the Topcon Corporation, is to become the exclusive distributor of the Pascal Photocoagulator in key European markets.

The Pascal (Pattern Scan Laser) Photocoagulator is a device that has been designed to optimize the treatment of eye diseases by applying a predetermined pattern array of up to 56 laser spots to the retina within 0.6 seconds.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
A person sits at their laptop with a cup of coffee visible in the foreground. Concept image for instant coffee, AMD, age related macular degeneration, ocular health and instant coffee investigation. Image credit: ©Ljustina – stock.adobe.com

Patients with high genetic risk of AMD should avoid instant coffee, investigators say

Lynda Charters
July 1st 2025
Article

Investigators obtained data from genome‐wide association studies to examine the effects of instant coffee consumption

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
European Commission grants label extension for Eylea 8 mg with extended 6-month treatment interval

European Commission grants label extension for Eylea 8 mg with extended 6-month treatment interval

Martin David Harp
June 30th 2025
Article
Iridex enrolls first patient in study evaluating MicroPulse technology as an adjunct to anti-VEGF therapy for DME

Iridex enrolls first patient in study evaluating MicroPulse technology as an adjunct to anti-VEGF therapy for DME

Martin David Harp
June 26th 2025
Article

The study will be led by principal investigator professor Noemi Lois, MD, PhD, FRCS(Ed), FRCOphth, at Queen’s University Belfast, in over 20 clinical sites, and plans to enroll 264 patients across the UK with severe DME.

From left, clockwise: scans of a patient's left and right eyes; a photo of article author Johann Krüger, MD; Dr Krüger's handwritten notes from a custom match IOL implantation

Custom matching IOLs is key to managing patient satisfaction

Johann Krüger, MD
June 26th 2025
Article

Johann Krüger, MD, shares insights from 26 years of experience

A digital rendering of the earth with a digital overlay to demonstrate technology. Concept image for global impact of myopia. Image credit: ©VFX – stock.adobe.com

Myopia’s global impact, by the numbers

Gregory Ostrow, MD;Laura Kirkeby, CO
June 25th 2025
Article

The global prevalence of myopia has surged, and is expected to affect nearly 5 billion people by 2050

© 2025 MJH Life Sciences

All rights reserved.